Skip to main content
. 2022 Aug 17;195(3):333–340. doi: 10.1007/s10549-022-06703-3

Table 3.

Adverse events

Total cohort Neratinib monotherapy Neratinib with capecitabine
n (%) n (%) n (%)
Grade 3–4 haematological AEs 2 (3) 0 (0) 2 (4)
Grade 3–4 non-haematological AEs 13 (18) 7 (26) 6 (13)
Any grade of diarrhoea 46 (64) 18 (67) 28 (62)
Grades of diarrhoea
 1 27 (38) 12 (44) 15 (33)
 2 12 (17) 4 (15) 8 (18)
 3 7 (10) 2 (7) 5 (11)
Dose reduction 17 (24) 4 (15) 13 (29)
Dose delaysa 34 (47) 13 (48) 21 (47)

AE Adverse event

aDose delay on at least one occasion